Drug-induced liver injury following the use of tocilizumab or sarilumab in patients with coronavirus disease 2019

Abstract Backgrounds Interleukin-6 (IL-6) blockers including tocilizumab and sarilumab were approved by the U.S. Food and Drug Administration (FDA) in June 2021 for the treatment of patients with moderate to severe COVID-19. The use of sarilumab or tocilizumab in COVID-19 patients has been related t...

Full description

Bibliographic Details

Published in:	BMC Infectious Diseases
Main Authors:	Qian Gao, Xuedong Yin, Boyu Tan, Junshi Wang, Jiayan Chen, Bin Zhao, Qiaoling Yang, Zhiling Li
Format:	Article
Language:	English
Published:	BMC 2022-12-01
Subjects:	Coronavirus disease 2019 (COVID-19) Tocilizumab Sarilumab Drug Induced Liver Injury FAERS Epidemiology
Online Access:	https://doi.org/10.1186/s12879-022-07896-0